About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do
not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment …

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer.
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …

Whether and how cancer-associated fibroblasts induce trastuzumab resistance in HER2+
breast cancer is still elusive. We analyzed the percentage of cancer stem cells and multiple …

Trastuzumab-refractory breast cancer stem cells (CSCs) could explain the high rate of
primary resistance to single-agent trastuzumab in HER2 gene-amplified breast cancer …

Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …

Despite the implementation of multiple HER2-targeted therapies, patients with advanced
HER2+ breast cancer ultimately develop drug resistance. Stromal fibroblasts represent an …

Pioneering clinical studies in de novo refractoriness to the anti-HER2 monoclonal antibody
trastuzumab have suggested that HER2 gene-amplification can take place also in a basal …

Despite the availability of multiple human epidermal growth factor receptor 2–targeted
(HER2-targeted) treatments, therapeutic resistance in HER2+ breast cancer remains a …

Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major
hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the …

Understanding the signaling differences that distinguish human HER2-amplified (HER2-
positive (HER2+)) breast cancers from other breast cancer subtypes may help to identify …